XETRA

DeFi Technologies' Subsidiary Valour Inc. Announces Plans to Launch a Physical Backed ETP, the Valour HBAR Staking ETP in Collaboration with The Hashgraph Association (THA)

Retrieved on: 
Monday, January 22, 2024
Bitcoin, Carbon, Cryptocurrency, XETRA, University, The Company, DLT, IBM, OTC, POS, Electronics, ETP, Standard Bank, Deutsche Telekom, Dell, Organization, NEO, LG Electronics, THA

Hedera's Significance: Hedera is a leading decentralized and open-source public network, notable for its energy-efficient Proof-of-Stake (PoS) consensus mechanism.

Key Points: 
  • Hedera's Significance: Hedera is a leading decentralized and open-source public network, notable for its energy-efficient Proof-of-Stake (PoS) consensus mechanism.
  • Hedera is a decentralized, open-source, proof-of-stake public ledger that utilizes the leaderless, asynchronous Byzantine Fault Tolerance (aBFT) hashgraph consensus algorithm.
  • Valour also recently announced the launch of the 1Valour Bitcoin Physical Carbon Neutral ETP (ISIN: GB00BQ991Q22) on June 15, 2023.
  • Additionally, Valour offers fully hedged digital asset ETPs, with listings across European exchanges, banks, and broker platforms.

Commerzbank AG: Announcement pursuant to Art. 5(1) lit. a) of Regulation (EU) No 596/2014 and Art. 2(1) of Delegated Regulation (EU) 2016/1052 / (Share Buyback Programme 2024)

Retrieved on: 
Saturday, January 13, 2024
European Parliament, Commission, Frankfurt Stock Exchange, Aktiengesellschaft, Commerzbank, European, Annual, Share repurchase, Acquisition, EUR, Council, XETRA, Security (finance)

2(1) of Delegated Regulation (EU) 2016/1052 / (Share Buyback Programme 2024)

Key Points: 
  • 2(1) of Delegated Regulation (EU) 2016/1052 / (Share Buyback Programme 2024)
    The issuer is solely responsible for the content of this announcement.
  • The purpose of the share buyback is the reduction of the share capital of Commerzbank AG.
  • The Share Buyback Programme 2024 will be carried out based on the authorization of the Annual General Meeting of Commerzbank AG on May 13, 2020.
  • The credit institution instructed with the purchase of shares of Commerzbank AG has been obligated accordingly by Commerzbank AG.

EQS-News: NAGA delivers a strong 2023 with EUR 45.5 million revenue and highest EBITDA in the company's history of EUR 7 million

Retrieved on: 
Saturday, January 13, 2024
XETRA, NAGA Group, Cost, News, EUR, Marketing, Cryptocurrency

NAGA delivers over EUR 45.5 million in revenue (FY2022: EUR 57 million)  and achieves a preliminary EBITDA of EUR 7 million (FY2022: - EUR 13.7 million) which is the highest EBITDA in the company's history, marking an impressive turnaround on the bottom line during challenging market conditions.

Key Points: 
  • NAGA delivers over EUR 45.5 million in revenue (FY2022: EUR 57 million)  and achieves a preliminary EBITDA of EUR 7 million (FY2022: - EUR 13.7 million) which is the highest EBITDA in the company's history, marking an impressive turnaround on the bottom line during challenging market conditions.
  • During 2023 NAGA saw over 132,000 account openings (FY22: 243,000) and more than 9.2 million trades (FY22: 8.6 million) whereof 4.8 million were copy trades (FY22: 3.5 million.
  • As a result all unique user metrics have shown a strong uptrend with higher average activity, deposit size and lifetime value.
  • Marketing expenses stood at EUR 5.5 million (FY2022: EUR 28.5 million), leading to the best ever gross Cost Per Acquisition of EUR 447 (FY22: EUR 1510) per new capitalized trading account.

EQS-News: Advanced Blockchain AG: Blockchain business models benefit from the approval of the Bitcoin Spot ETF

Retrieved on: 
Saturday, January 13, 2024
ETF, XETRA, Exchange-traded fund, Investment, Fidelity, BlackRock, AB, Blockchain, Security (finance), Cryptocurrency

January 11, 2024 - Yesterday evening, January 10, 2024, the Securities and Exchange Commission (SEC) granted approval for the first Exchange Traded Fund (ETF) for Bitcoin spot trading.

Key Points: 
  • January 11, 2024 - Yesterday evening, January 10, 2024, the Securities and Exchange Commission (SEC) granted approval for the first Exchange Traded Fund (ETF) for Bitcoin spot trading.
  • Simon Telian, CEO of AB, comments: "The approval of Bitcoin Spot ETFs marks a significant milestone in the recognition and integration of cryptocurrencies into the traditional financial world.
  • The SEC approval is expected to result in inflows into the Bitcoin Spot ETFs of up to 4 billion US dollars on the first day of trading.
  • I am extremely confident that this move will significantly increase interest in our blockchain and crypto offerings and have a positive impact on our business development."

EQS-News: Northern Data Group announces closing of Damoon acquisition

Retrieved on: 
Monday, January 8, 2024
Tether, Cloud, Taiga, NB2, XETRA, Synthetic media, Frankfurt, Acquisition, ART, Frankfurt Stock Exchange, Bank statement, Cloud computing, GPU, Innovation, Generative, Deep learning super sampling, Investment, EUR, Ticker, NVIDIA, Exercise, Security (finance)

Frankfurt/Main – 8 January 2024 – Northern Data AG (‘Northern Data Group’; Ticker symbol German stock market: NB2 , ISIN: DE000A0SMU87 ) today announces the completion of the acquisition of Damoon Limited, formerly Damoon Designated Activity Company (‘Damoon’)’ from Tether Group.

Key Points: 
  • Frankfurt/Main – 8 January 2024 – Northern Data AG (‘Northern Data Group’; Ticker symbol German stock market: NB2 , ISIN: DE000A0SMU87 ) today announces the completion of the acquisition of Damoon Limited, formerly Damoon Designated Activity Company (‘Damoon’)’ from Tether Group.
  • The closing of the transaction now makes Tether Group, one of the world’s most successful and innovative blockchain technology companies, the cornerstone shareholder in Northern Data Group.
  • In total, including the recently announced purchases , Northern Data Group now owns more than 18,000 NVIDIA H100 Tensor Core GPUs.
  • Thereby, Northern Data acquired 69.92% of Damoon, as well as 69.92% of the c. EUR 400 million shareholder loan granted to Damoon by Tether Group.

Northern Data Group announces closing of Damoon acquisition

Retrieved on: 
Monday, January 8, 2024
Tether, Cloud, Taiga, NB2, XETRA, Synthetic media, Acquisition, ART, Frankfurt Stock Exchange, Bank statement, Cloud computing, GPU, Generative, Deep learning super sampling, EUR, Investment, Ticker, NVIDIA, Exercise, Security (finance)

FRANKFURT, Germany, Jan. 8, 2024 /PRNewswire/ -- Northern Data AG ('Northern Data Group') (Ticker symbol German stock market: NB2) (ISIN: DE000A0SMU87) today announces the completion of the acquisition of Damoon Limited, formerly Damoon Designated Activity Company ('Damoon')' from Tether Group.

Key Points: 
  • FRANKFURT, Germany, Jan. 8, 2024 /PRNewswire/ -- Northern Data AG ('Northern Data Group') (Ticker symbol German stock market: NB2) (ISIN: DE000A0SMU87) today announces the completion of the acquisition of Damoon Limited, formerly Damoon Designated Activity Company ('Damoon')' from Tether Group.
  • The closing of the transaction now makes Tether Group, one of the world's most successful and innovative blockchain technology companies, the cornerstone shareholder in Northern Data Group.
  • Thereby, Northern Data acquired 69.92% of Damoon, as well as 69.92% of the c. EUR 400 million shareholder loan granted to Damoon by Tether Group.
  • With the registration of a further increase of its share capital against contribution in kind by EUR 6,556,949 to EUR 48,734,180 on 3 January 2024, Northern Data Group acquired the remaining 30.08% of Damoon and of the shareholder loan granted to Damoon in implementation of the exercise of the call option granted to Northern Data Group in the Investment Agreement, as already announced in September 2023, thereby fully completing the acquisition of Damoon and the shareholder loan granted to Damoon.

Newron Reports Exceptional One-year Results of Study 014/15 With Evenamide in Treatment-resistant Schizophrenia (TRS)

Retrieved on: 
Thursday, January 4, 2024
Science, Biotechnology, Research, Pharmaceutical, Health, Mental Health, Clinical Trials, Other Health, Psychiatry, XETRA, ADOS, Medication, Positive, Incidence, Clinical Global Impression, CNS, Molecular medicine, PANSS, EKG, Weight gain, Longevity, Peripheral nervous system, TRS, Patient, Pharmaceutical industry

The data demonstrated that treatment with evenamide was associated with sustained clinically significant benefit that increased throughout the one-year course of treatment.

Key Points: 
  • The data demonstrated that treatment with evenamide was associated with sustained clinically significant benefit that increased throughout the one-year course of treatment.
  • In contrast to common clinical experience, no patient “relapsed” during the one-year treatment period.
  • Ravi Anand, Newron’s Chief Medical Officer, said: “Treatment with evenamide as an add-on to antipsychotics in TRS patients has produced benefits that have never been reported before.
  • The presentation for this conference call can be downloaded as of today, January 4, 2024, at 7 am CET, on Newron’s website ( https://www.newron.com/investors/reports-and-presentation/year/2024 ).

EQS-News: Newron reports exceptional one-year results of study 014/15 with evenamide in treatment-resistant schizophrenia (TRS)

Retrieved on: 
Thursday, January 4, 2024
Psychiatry, XETRA, ADOS, Positive, Incidence, Clinical Global Impression, CNS, Molecular medicine, PANSS, EKG, Weight gain, Longevity, Peripheral nervous system, TRS, Patient, Pharmaceutical industry

The data demonstrated that treatment with evenamide was associated with sustained clinically significant benefit that increased throughout the one-year course of treatment.

Key Points: 
  • The data demonstrated that treatment with evenamide was associated with sustained clinically significant benefit that increased throughout the one-year course of treatment.
  • In contrast to common clinical experience, no patient “relapsed” during the one-year treatment period.
  • 25% of all patients achieved “remission” (see “About remission”), never described before in TRS patients.
  • The presentation for this conference call can be downloaded as of today, January 4, 2024, at 7 am CET, on Newron’s website ( https://www.newron.com/investors/reports-and-presentation/year/2024 ).

Newron Completes Enrollment of Schizophrenia Patients in Potentially Pivotal Study 008A With Evenamide

Retrieved on: 
Friday, December 29, 2023
Science, Neurology, Other Science, Biotechnology, Pharmaceutical, General Health, Health, Mental Health, Peripheral nervous system, Patient, Medication, Safety, XETRA, Schizophrenia, Pharmaceutical industry

Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced the completion of patient enrollment in study 008A, its potentially pivotal study with evenamide in patients suffering from schizophrenia.

Key Points: 
  • Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced the completion of patient enrollment in study 008A, its potentially pivotal study with evenamide in patients suffering from schizophrenia.
  • Study 008A is a four-week, randomized, double-blind and placebo-controlled study assessing the efficacy, tolerability, and safety of evenamide (30 mg bid) in patients with chronic schizophrenia currently being treated with a second-generation antipsychotic, but who demonstrate an inadequate response to that treatment.
  • A total of 290 patients were enrolled at study centers in Europe, Asia and Latin America.
  • If positive, study 008A would be the first well-controlled study to demonstrate the clinical utility of evenamide in schizophrenia patients who show an inadequate response to treatment with atypical antipsychotics.

EQS-News: Status of the share buyback: 27 November to 1 December 2023

Retrieved on: 
Saturday, December 30, 2023
Acquisition, EUR, Share repurchase, Council, European, European Parliament, XETRA, Treasury, Notice

Status of the share buyback: 27 November to 1 December 2023

Key Points: 
  • Status of the share buyback: 27 November to 1 December 2023
    The issuer is solely responsible for the content of this announcement.
  • In the period from 27 November to 1 December 2023, init innovation in traffic systems SE (ISIN DE0005759807) acquired 5,079 treasury shares at a value of EUR 161,761.58.
  • The acquisition was carried out by the assigned bank via the stock exchange (XETRA).
  • Information about individual transactions and daily trading volumes is published online under the following link: